Payment overview · 2025
General Payments
$529.62
28 reported records · 11 companies
Healthcare provider profile · identity verified
Alka Vaishali Sachdeva, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RALEIGH, NC · NPI 1265441950
Verified facts
What the public records show
CMS Open Payments records show Alka Vaishali Sachdeva, MD received $529.62 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.97 | 34.4% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.98 | 12.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.62 | 11.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.60 | 8.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.27 | 7.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.93 | 6.8% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $25.18 | 4.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.01 | 4.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.86 | 3.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.07 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.13 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.62 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.64 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.98 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 87 |
| Lisinopril | Lisinopril | 272 | 87 |
| Losartan Potassium | Losartan Potassium | 257 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 71 |
| Metformin Hcl Er | Metformin Hcl | 156 | 47 |
| Gabapentin | Gabapentin | 155 | 54 |
| Omeprazole | Omeprazole | 150 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 45 |
| Simvastatin | Simvastatin | 129 | 42 |
| Metformin Hcl | Metformin Hcl | 123 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 24 |
| Trazodone Hcl | Trazodone Hcl | 77 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 24 |
| Sertraline Hcl | Sertraline Hcl | 73 | 23 |
| Glipizide | Glipizide | 69 | 24 |
| Bupropion Xl | Bupropion Hcl | 67 | 22 |
| Carvedilol | Carvedilol | 67 | 22 |
| Alendronate Sodium | Alendronate Sodium | 66 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 23 |
| Jardiance | Empagliflozin | 62 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 19 |
| Rybelsus | Semaglutide | 54 | 16 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Allopurinol | Allopurinol | 48 | 17 |
| Furosemide | Furosemide | 46 | 20 |
| Ozempic | Semaglutide | 46 | 13 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Celecoxib | Celecoxib | 44 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Mirtazapine | Mirtazapine | 40 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alprazolam | Alprazolam | 22 | 11 |
| Eliquis | Apixaban | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 16 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Clonazepam | Clonazepam | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $529.62 · 28 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CONTRAVE, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error